MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies by Scott, Elizabeth et al.
  
 
 
 
Scott, E., Loya, K., Mountford, J., Milligan, G., and Baker, A.H. (2013) 
MicroRNA regulation of endothelial homeostasis and commitment—implications 
for vascular regeneration strategies using stem cell therapies. Free Radical 
Biology and Medicine, 64 . pp. 52-60. ISSN 0891-5849 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/86830 
 
 
 
Deposited on:  18 October 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Free Radical Biology and Medicine 64 (2013) 52–60Contents lists available at ScienceDirectFree Radical Biology and Medicine0891-58
http://d
Abbre
cell; hE
induced
endothe
$This
Commo
mits no
the orig
n Corr
E-mjournal homepage: www.elsevier.com/locate/freeradbiomedReview ArticleMicroRNA regulation of endothelial homeostasis and
commitment—implications for vascular regeneration
strategies using stem cell therapies$
Elizabeth Scott a, Komal Loya a, Joanne Mountford b, Graeme Milligan c, Andrew H. Baker a,n
a Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow,
Glasgow G12 8TA, UK
b Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, UK
c Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow G12 8QQ, UKa r t i c l e i n f o
Available online 9 May 2013
Keywords:
MicroRNA
Embryonic stem cells
Induced pluripotent stem cells
Pluripotency
Vascular endothelial cells
Regenerative medicine
Free radicals49/$ - see front matter & 2013 The Authors. P
x.doi.org/10.1016/j.freeradbiomed.2013.04.037
viations: CVD, cardiovascular disease; miRNA
SC, human embryonic stem cell; mESC, murin
pluripotent stem cell; EPC, endothelial proge
lial growth factor; ROS, reactive oxygen spec
is an open-access article distributed unde
ns Attribution-NonCommercial-No Derivative
n-commercial use, distribution, and reproduct
inal author and source are credited.
esponding author. Tel.: +44 141 330 1977; fax
ail address: Andrew.H.Baker@Glasgow.ac.uk (Aa b s t r a c t
Human embryonic (hESC) and induced pluripotent (hiPSC) stem cells have broad therapeutic potential in the
treatment of a range of diseases, including those of the vascular system. Both hESCs and hiPSCs have the
capacity for indeﬁnite self-renewal, in addition to their ability to differentiate into any adult cell type. These
cells could provide a potentially unlimited source of cells for transplantation and, therefore, provide novel
treatments, e.g. in the production of endothelial cells for vascular regeneration. MicroRNAs are short, noncoding
RNAs that act posttranscriptionally to control gene expression and thereby exert inﬂuence over
a wide range of cellular processes, including maintenance of pluripotency and differentiation. Expression
patterns of these small RNAs are tissue speciﬁc, and changes in microRNA levels have often been associated
with disease states in humans, including vascular pathologies. Here, we review the roles of microRNAs in
endothelial cell function and vascular disease, as well as their role in the differentiation of pluripotent stem cells
to the vascular endothelial lineage. Furthermore, we discuss the therapeutic potential of stem cells and how
knowledge and manipulation of microRNAs in stem cells may enhance their capacity for vascular regeneration.
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.H. Baker).Introduction
Accounting for around 17 million deaths in 2008 (http://www.
who.int/gho/ncd/mortality_morbidity/cvd/en/index.html), cardio-
vascular disease (CVD) is one of the leading causes of mortality
worldwide. Current therapies are limited and, therefore, the
derivation of new and novel treatments is of great importance.
Regenerative medicine is one important area of research for the
development of novel treatments, and in recent years, a great deal
of focus has been on the use of pluripotent stem cells for the repair
and regeneration of diseased and damaged tissues.reserved.
E. Scott et al. / Free Radical Biology and Medicine 64 (2013) 52–60 53Pluripotent stem cells have the ability to differentiate into any
cell of the three germ layers, mesoderm, endoderm, and ectoderm,
thus potentially allowing for generation of any fetal or adult cell
type. Human ESCs are derived from the inner cell mass of the
blastocyst stage of a developing human embryo. First cultured in
1998 [1], these cells are capable of indeﬁnite self renewal, while
maintaining their pluripotency and a normal karyotype. Human
ESCs are thought to have great potential as a potentially unlimited
source for the derivation of functional, transplantable cells for the
treatment of a wide range of diseases. However, therapeutic
transplantation of these cells into a patient would be allogeneic,
thus carrying the risk of rejection by the recipient, and this source
of cells is also considered to be ethically challenging by some.
Thus, in recent years, research has focused on identifying popula-
tions of autologous pluripotent cells, which may be used in
therapeutic transplantation without the risk of rejection, and
which are more ethically acceptable. Reprogramming of a patient’s
own somatic cells, using a combination of deﬁned factors, includ-
ing Oct3/4, Klf4, Sox2, and c-Myc, as well as Nanog and Lin28, has
now been achieved, and these “personalized” pluripotent stem
cells are known as induced pluripotent stem cells (iPSCs) [2,3]. The
ability of stem cells to maintain pluripotency and differentiate into
any adult or fetal cell type is governed by complex interactions
between transcription factors, epigenetic changes, signaling path-
ways, and microRNAs.
Discovered in Caenorhabditis elegans [4,5], microRNAs (miRNAs)
are noncoding RNAs approximately 22 nucleotides in length. Control-
ling a number of important cellular functions, miRNAs exert their
effects by acting posttranscriptionally to control translation of mes-
senger RNAs (mRNAs) [6], through a binding site in the 3′ untranslated
region (UTR) of the mRNA. Before being processed into their mature
form, miRNAs are transcribed as primary miRNAs in the nucleus by
RNA polymerase II [7]. These primary transcripts then undergo
processing within the nucleus by an RNase III-type enzyme known
as Drosha [8], along with DiGeorge syndrome critical region gene 8
(DGCR8), a double-stranded DNA-binding protein. This processing
results in the formation of pre-miRNAs, miRNA precursors with amiR-92a
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N-terminal kinases; HOXA5, homeobox A5; GAX, growth arrest-speciﬁc homeobox; ZEBstem–loop structure, 70 nucleotides in length, which are then
transported out of the nucleus and into the cytoplasm via exportin 5
[9]. Once in the cytoplasm, pre-miRNAs undergo further processing by
Dicer [10], another RNase III-type enzyme, leaving short (22 nt)
double-stranded mature miRNAs. A single strand of this mature form
is then incorporated into the RNA-induced silencing complex, which
then binds the 3′UTR of a target mRNA, determined by the seed
sequence, nucleotides 2–8 in the mature miRNA, thought to control
miRNA target speciﬁcity. Here, the miRNA acts to control translation in
one of two main ways, either inhibition of translation or targeting of
the mRNA for degradation [11], depending on the complementarity
between the seed sequence of the miRNA and the binding site in the 3′
UTR. Additionally, although unusual, it has also been shown that
miRNAs may occasionally act to increase protein levels [12]. It is
hypothesized that there are more than 1000 miRNAs in the human
genome, with each miRNA working to control the translation of a
network of genes. Patterns of miRNA expression levels are generally
tissue speciﬁc, and dysregulation can lead to cellular dysfunction.
Indeed, miRNAs have been implicated in a number of diseases,
including cancer [13] and metabolic disease [14], as well as CVD [15].MiRNAs and the vascular endothelium
Endothelial cells (ECs) play an important role in vascular develop-
ment during embryogenesis, and are responsible for the maintenance
of vascular integrity with respect to angiogenesis and wound repair
after vascular injury [16]. Several miRNAs have been identiﬁed to play
a role in the regulation of function, proliferation, and growth of vas-
cular ECs [17]. These include miR-126, the proangiogenic miR-17–92
cluster, and the antiangiogenic miR-221 and -222. The roles of Dicer
and Drosha, the aforementioned main miRNA processing enzymes,
have been studied previously in ECs [18,19]. Combined in vitro small
interfering RNA silencing of both Dicer and Drosha reduced the
sprout-forming and angiogenic properties of ECs [20].
One of the most extensively characterized EC miRNAs is
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in the vasculature of both the heart and the lungs [16].
Endothelial-speciﬁc deletion of miR-126 in mouse embryos is
lethal in 40% of cases, causing hemorrhaging and rupturing of
blood vessels during development. In the surviving miR-126-null
mice, EC integrity is severely hampered because of a lack of tight
cell–cell interactions. It has also been demonstrated that miR-126
targets the expression of Spred-1. Spred-1 inhibits intracellular
angiogenic signaling, consequently promoting the formation of
blood vessels by enhancing the proangiogenic properties of
vascular endothelial growth factor (VEGF) and ﬁbroblast growth
factor (FGF) (Fig. 1). Therefore, miR-126 expression serves to “limit”
the antiangiogenic effects of Spred-1. MiR-126 also regulates the
expression of vascular cell adhesion molecule 1 (VCAM-1), a
critical adhesion molecule, which allows for EC:leukocyte adher-
ence. Reduced expression of miR-126, in tumor necrosis factor-α-
stimulated ECs, increases the expression of VCAM-1 and, in turn,
enhances leukocyte adherence and, ultimately, vascular inﬂamma-
tion [21]. MiRNA-126 is also expressed in mature vessel ECs, where
it targets p85β, a subunit of phosphatidylinositol 3-kinase. This
inhibits the function of angiopoietin-1, which plays an important
role in vessel stabilization and maturation [22].
The miR-17-92 cluster, containing miR-17, -18a, -19a/b, -20a,
and -92a, is expressed in ECs and has been shown to play a role in
tumor angiogenesis. p53-null mouse-derived colonic epithelial
cells transformed with Kras, and then additionally transduced
with c-Myc, produced large tumors, with enhanced neovascular-
ization in vivo [23]. This correlates with a downregulation of
thrombospondin-1 (Tsp1), an antiangiogenic factor, and other
related proteins, such as connective tissue growth factor (CTGF),
both of which are predicted targets of the miR-17-92 cluster. The
miR-17-92 cluster is upregulated in these tumors, and knockdown
causes partial restoration of Tsp1 and CTGF levels [23]. Tsp1 is also
a predicted target of let-7f and miR-27b, two miRNAs whose
expression is reduced in endothelial cells after silencing of Dicer
and Drosha [20]. MiRNA-130a is also thought to play a proangio-
genic role in ECs by inhibiting the expression of GAX, a home-
odomain gene, also known as MEOX2, which is implicated in the
inhibition of angiogenesis in vascular ECs. It has also been shown
to inhibit the function of another antiangiogenic homeobox gene,
HOXA5, suggesting that it could be a potential regulator of the
angiogenic phenotype of vascular ECs [24]. Taken together, these
ﬁndings demonstrate that proangiogenic miRNAs, such as the
miR-17-92 cluster, let-7f, and miR-27b, promote angiogenesis in
vascular ECs via the targeting and subsequent repression of
antiangiogenic factors, for example, Tsp1 and GAX (Fig. 1).
Proangiogenic endothelial-associated miRNAs also function
by targeting growth factors and their receptors, both directly
and indirectly (Fig. 1). For example, as previously mentioned,
the angiogenic properties of miR-126 have been well character-
ized, as it functions to enhance VEGF and FGF signaling via the
targeting of Spred-1 [16]. Working in a similar way, via indirect
targeting of growth factors, miR-296 targets hepatocyte growth
factor-regulated tyrosine kinase substrate (HGS), leading to its
suppression [25]. A reduction in the expression of HGS results in
a decrease in HGS-mediated degradation of two growth factor
receptors: vascular endothelial growth factor receptor 2
(VEGFR2) and platelet-derived growth factor receptor β
(PDGFR-β). Another angiogenic miRNA, miR-10, also acts via
the promotion of VEGF signaling. In human umbilical vein
endothelial cells (HUVECs), it has been shown that miR-10
targets and, therefore, causes a decrease in Flt1 protein expres-
sion. Flt1 is thought to sequester VEGF, hence preventing the
binding of VEGF to VEGFR2, and thus antagonizing VEGFR2-
mediated signaling. Therefore, miR-10 exerts its angiogenic
affects via the promotion of VEGFR2-mediated signaling, tocontrol EC proliferation, migration, and adhesion [26]. This
suggests that miR-126, -296, and -10 may represent new
therapeutic targets in the selective modulation of angiogenesis.
Reduced miR-210 expression has been shown to inhibit EC
growth and induce apoptosis, suggesting a proangiogenic role for
this miRNA. In hypoxic ECs, it has been shown that miR-210 levels
are increased compared to cells under normoxic conditions,
leading to changes in cell survival, migration, and differentiation.
This effect is thought to be through its direct targeting of the
membrane-bound ephrin-A3 [27]. Ephrins bind to Eph receptor
tyrosine kinases to exert their effects on a number of signaling
pathways within the cell. Previously Eph receptors and their
ephrin ligands have been shown to play an important role in the
development of the cardiovascular system and vascular remodel-
ing [28] and, therefore, it may be speculated that ephrin-A3 has an
important role in the control of angiogenesis. A recent report has
further elucidated the role of miR-210 in angiogenesis, by using
lentiviral-mediated overexpression of miR-210 in HUVECs. This
study demonstrated an induction of capillary formation, due to
upregulation of Notch-1 signaling molecules, which facilitate
migration of endothelial cells [29,30]. MiR-210, therefore, could
also be used as a therapeutic target for the modulation of
angiogenesis in the treatment of ischemic diseases. Similarly, a
proangiogenic role has also been suggested for miR-378, a miRNA
previously studied in a number of cancer cell lines. Like miR-210, it
was shown that expression of miR-378 enhanced cell survival and
decreased apoptosis, while also causing increased tumorigenesis
and angiogenesis [31]. All three of these functions were thought to
occur through miR-378 targeting of two different tumor suppres-
sor genes, suppressor of fused (Sufu) [32], whose loss of function
causes excessive tumor cell proliferation [33], and tumor suppres-
sor candidate 2 (Fus-1) [34], suggesting a possible therapeutic role
for miR-378 in the control and prevention of tumor angiogenesis.
A number of antiangiogenic miRNAs have also been identiﬁed
and, like those identiﬁed as proangiogenic, may also be useful
targets allowing for the control of angiogenesis in the treatment of
cardiovascular diseases. In HUVECs, high expression of antiangio-
genic miRNAs that have been shown to target receptors of a
variety of angiogenic factors has been observed (Fig. 1). MiR-221
and -222 target the protein expression of c-kit, the receptor for
stem cell factor (SCF), without affecting the mRNA levels. The
interaction of these two miRNAs with c-kit modulates the ability
of endothelial cells to form new capillaries, consequently regulat-
ing the angiogenic activity of SCF, and is also thought to inhibit
endothelial cell proliferation and migration [35]. MiRNA-221 and
-222 also inhibit the tube formation and wound healing ability of
endothelial cells in vitro [35], conﬁrming their antiangiogenic
properties. MiRNA-221 also exerts its antiangiogenic effects via a
strong upregulation of GAX, a potential master regulator of EC
angiogenic phenotype [36], through downregulation of ZEB2, a
zinc-ﬁnger nuclear factor that primarily acts as a transcriptional
repressor [37], resulting in an inhibition of angiogenesis [38]. Like
miR-221 and -222, miR-92a has also been shown to have anti-
angiogenic properties. Inhibition of this miR-92, transcribed as
part of the miR-17-92 cluster, enhanced proliferation and migra-
tion in rat aortic ECs in vitro and also enhanced reendothelializa-
tion in injured rat carotid arteries in vivo [39].
Moreover, miR-15b and -16, along with miR-20a and -20b, are
also thought to have antiangiogenic properties, acting through the
targeting of VEGF [40]. All four miRNAs were downregulated in
carcinoma cells during induction of hypoxia, along with the
corresponding hypoxia-induced increase in VEGF expression,
allowing for promotion of angiogenesis. As well as VEGF, other
angiogenic factors were also found to be targets of all or some of
these miRNAs, including COX2, c-MET, and uPAR. Again, these data
suggest a possible role for these miRNAs in the treatment and
E. Scott et al. / Free Radical Biology and Medicine 64 (2013) 52–60 55regulation of angiogenesis in carcinomas. Another miRNA that has
been identiﬁed as an antiangiogenic modulator is miR-100 [41].
Expressed in both ECs and vascular smooth muscle cells (VSMC),
miR-100 was found to be downregulated during induction of
hypoxia in vivo and was shown to negatively regulate the levels
of mammalian target of rapamycin (mTOR), a gene required for
angiogenesis and endothelial cell proliferation in response to
hypoxia [42]. Like many of the other miRNAs mentioned, control
of miR-100 has therapeutic potential in the treatment of ischemic
conditions via the stimulation of new blood vessel growth, as well
as in the treatment of other mTOR-dependent processes.
MiR-181a is also thought to play an important role during
vascular development. It targets Prox1, a homeobox gene shown to
be involved in the development of the lymphatic system [43], in
primary lymphatic ECs and reprograms these cells toward a blood
vascular phenotype, thereby determining cell fate, a key process
during development [44]. The closely related miR-181b is also
widely expressed in the vascular endothelium and has been
identiﬁed as a regulator of NF-κB-mediated vascular inﬂammation,
via targeting of importin-α3. Importin-α3 is involved in the nuclear
translocation of NF-κB, and targeting of importin-α3, therefore,
leads to the suppression of a set of NF-κB target genes, such as
VCAM-1 and E-selectin [45]. These two molecules are involved in
adhesion, and suppression leads to a reduction in leukocyte
adhesion and vascular inﬂammation in vivo. This may, therefore,
suggest that miR-181b has potential as a target for the control of
vascular inﬂammation.Dysregulation of miRNAs in endothelial cells
Variations in miRNA expression levels have been implicated in
changes in EC phenotype, potentially resulting in vascular dys-
function and ultimately the development of disease. Identiﬁcation
of these miRNAs and the mechanisms by which they exert their
effects may lead to the discovery of new targets for the treatment
of vascular disease.
Differential expression of subsets of endothelial miRNAs has
been observed in athero-susceptible and athero-protected
endothelial regions in vivo [46]. Fang et al. [47] hypothesized that
miRNAs differentially expressed in these two distinct endothelial
phenotypes may work to target Krüppel-like factors 2 and 4 (KLF2
and KLF4), factors that regulate gene networks associated with
athero-protective properties. The authors demonstrated that miR-
92a suppresses the expression of these two factors, therefore
suggesting that miR-92a plays an important role in arterial home-
ostasis and could be used as a possible target in the treatment and
prevention of atherosclerosis.
Caporali et al. [48] demonstrated that miRNAs also play a role
in diabetes mellitus-induced endothelial dysfunction. Diabetes
mellitus can induce a number of vascular-associated problems,
with intracellular hyperglycemia leading to both endothelial
dysfunction and microvascular rarefaction. MiR-503 was found to
be upregulated in diabetic and ischemic conditions, both in vitro
and in vivo. It was also found that overexpression of miR-503,
through the targeting of cell cycle-related proteins, resulted in
inhibition of EC proliferation and migration. This suggests that
miR-503 could be used as a novel therapeutic target in the
treatment of patients suffering from peripheral ischemic problems
as a result of diabetes mellitus.
Another miRNA reported to play a role in the regulation of
vascular disease is miR-320, which inhibits the glucose-induced
expression of endothelin-1, VEGF, and ﬁbronectin, genes asso-
ciated with chronic diabetic complications, in HUVECS. In diabetic
patients, therapeutic modulation of this miRNA could potentially
be used to control regulation of genes induced by high levels ofglucose [49]. High exposure to glucose, in diabetic patients, also
reduces the expression of miR-221. Reduction of miR-221 expres-
sion results in higher c-kit expression, thus further inducing c-kit-
mediated migration and homing of endothelial cells, important in
vascular tissue repair and regeneration. Thus, modulation of miR-
221 expression, and hence manipulation of the miR-221-c-kit
pathway, may be useful in the treatment of vascular dysfunction
in diabetic patients [50].
Endothelial progenitor cells (EPCs) remain a relatively poorly
deﬁned cell type. Derived from the bone marrow, they are
implicated in the repair and maintenance of the vasculature via
reendothelialization and neovascularization [51]. Previously, it has
been shown that the number of circulating EPCs, as well as their
function, decreases in response to risk factors associated with
coronary artery disease (CAD), including age, diabetes, and high
levels of blood cholesterol; however, the mechanisms behind this
are poorly understood. Zhang et al. [52] found that isolated EPCs
expressed a number of endothelial cell-speciﬁc angiogenesis-
associated miRNAs (miR-126, -221, -222, -130a, and -92a), sug-
gesting that this subset may play a role in the function of these
cells, particularly in the differentiation of these cells to mature
vascular endothelium. When levels of these miRNAs were com-
pared between healthy individuals and those suffering from CAD,
it was found that the expression of miR-126 was decreased,
whereas there were increases in the levels of miRNAs with
antiangiogenic properties, miR-221, -222, and -92a. Thus, dysre-
gulation of endothelial-associated miRNAs in EPCs may contribute
to the observed reduction in their regeneration capacity.MiRNAs in stem cells
Along with transcription factors, signaling pathways, epigenetic
changes and other noncoding RNAs, microRNAs form a complex
network that acts to control the two deﬁning functions of both
hESCs and hiPSCs: their capacity for indeﬁnite self-renewal and
ability to differentiate into any adult cell type. In pluripotent cells,
there exist pluripotency-regulating miRNAs, whose role it is to
inhibit the expression of factors associated with differentiation to
allow for continued self-renewal, and differentiation-promoting
miRNAs, which target mRNAs associated with pluripotency, and as
a result allow cells to differentiate.
Knockdown of Dicer [53,54] and DGCR8 or Drosha [55] in
murine ES cells (mESCs) results in severe defects in the differ-
entiation and self-renewal capacities of the cells and, therefore,
highlights the importance of miRNAs in both pluripotency and
differentiation of embryonic stem cells. In hESCs, knockdown of
Drosha or Dicer resulted in a longer cell cycle, as well as an
upregulation of a number of pluripotency-associated genes [56],
observations that are consistent with miRNAs playing a role in the
division and self-renewal of pluripotent stem cells. More speciﬁ-
cally, lentivirus-mediated knockdown of Dicer has also been
observed to cause signiﬁcant reduction in the ability of hESCs to
commit to the endothelial lineage [57], once again reinforcing the
importance of miRNAs in the differentiation of pluripotent
stem cells.
Maintenance of pluripotency in ES cells has been shown to be
regulated by a core network of stem cell-speciﬁc transcription
factors, comprising Nanog, Oct3/4, and Sox2, as well as other
pluripotency factors, including KLF4, c-Myc, and Lin28 [58].
Together, these factors work to form a positive autoregulatory
loop, driving self-renewal and preventing differentiation. MiRNA
expression in ES cells is thought to be controlled by these key
pluripotency factors, although the mechanism by which this is
executed is poorly understood. However, using both mESCs and
hESCs, Marson et al. [59] have shown that the core regulatory
E. Scott et al. / Free Radical Biology and Medicine 64 (2013) 52–6056factors Oct3/4, Nanog, and Sox2, as well as Tcf3, occupy the
promoter regions of miRNAs speciﬁcally expressed in ES cells.
These key regulators bind to the promoter regions of a subset
of miRNAs that are silenced in pluripotent ES cells, owing to the
presence of Polycomb group proteins, but become expressed at
increasing levels in a tissue-speciﬁc manner as cells differentiate
and become committed to speciﬁc lineages. Occupancy of promo-
ter regions of these miRNAs may allow for cells to be “primed,”
ready for rapid and efﬁcient differentiation [59].
In recent years, proﬁling of miRNAs has led to the identiﬁcation
of a subset of miRNAs that are preferentially expressed in ES cells
and embryonic tissue [60–62]. A number of ES-speciﬁc miRNAs
have been identiﬁed as having a signiﬁcant role in the mainte-
nance of pluripotency, including the miR-371 cluster, homologous
to the murine miR-290 cluster, the most abundant miRNAs in
mESCs [59]; the miR-302 cluster; and the miR-17-92 cluster [63].
These miRNAs were found to have similar seed sequences,
suggesting that there exists some overlap between the mRNA
targets of these miRNAs, with a number of shared targets being
key cell cycle regulators.
The miR-302 cluster, a long transcript containing a number of
miRNAs (miR-302b, miR-302c, miR-302a, miR-302d, and miR-
367), is expressed speciﬁcally in ES cells. Four of the eight miR-
302 miRNAs (that is, miR-302a, -b, -c, and -d) are highly homo-
logous in their mature forms, suggesting the existence of a number
of shared target mRNAs [64]. When tested in a number of different
hESC lines, the miR-302 cluster was shown to be consistently
downregulated during early differentiation [65]. Card et al. [66]
demonstrated that the transcription factors Nanog, Oct4, and Sox2
bind to the promoter region of the miR-302 cluster in hESCs and
that Sox2 and Oct4 were required for transcriptional regulation of
miR-302a. Oct4 and miR-302 also work together to regulate the
activity of NR2F2 (COUP-TFII), a member of the NR2F/COUP-TF
nuclear orphan receptor family of transcription factors, which is
transcriptionally activated during differentiation as Oct4 and miR-
302 levels decline [67]. This suggests that miR-302 expression
levels are important in pluripotency, working in a network along-
side well-characterized pluripotency-regulating transcription fac-
tors to ensure cells remain in their undifferentiated state.
In ES cells, the cell cycle allows for rapid proliferation, owing to
a shortened G1 phase and a higher proportion of cells in S phase
[68]. As cells differentiate this proﬁle changes, and cells begin to
undergo a cell cycle more similar to that of adult cells, which
incorporates a longer G1 phase. MiR-302a, when expressed in
primary nonpluripotent cells, was found to decrease the number
of cells in the G1 phase coupled with an increase in the number of
cells in S phase. Inhibition of this miRNA in pluripotent cells,
however, led to an increase in cells entering the G1 phase. The
miR-302 family targets a number of cell cycle-regulating proteins,
and Card et al. demonstrated that miR-302 acts posttranscription-
ally to control the expression of cyclin D1 [66]. As Oct4 and Sox2
activate transcription of miR-302, and miR-302 causes repression
of cell cycle-regulating proteins, it may be suggested that there
exists a link between key regulators of pluripotency (Oct4/Sox2)
and the control of the cell cycle in hESCs. Present in mature ECs,
the miR-17-92 cluster is also expressed in pluripotent stem cells,
as well as in a number of cancers, in which its expression has been
shown to increase in the presence of c-Myc [69]. Smith et al. [70]
showed that the miR-17-92 cluster, much like the miR-302 family,
controls the cell cycle in pluripotent cells by regulating a number
of cell cycle regulators, such as Rb2. The expression of miRNAs in
the miR-17 family has also been shown to be upregulated during
differentiation of mESCs [71]. MiRNAs, therefore, play a critical role
in cell cycle regulation in pluripotent stem cells, a process that is
important for their self-renewal—one of the deﬁning features of
ES and iPS cells.A number of critical determinants of pluripotency, Oct4, KLF4,
and Sox2, are targets of another miRNA, miR-145 [72]. This miRNA
is expressed at low levels in hESCs and is upregulated during
differentiation to repress self-renewal capacity and the expression
of pluripotency-associated genes. Sox2 is also regulated by miR-
126 [73], which also regulates KLF4, and its increased expression
represses pluripotency and the self-renewal capacity of human ES
cells [74]. These data suggest that these two miRNAs are involved
in the transition of the cell from pluripotency toward speciﬁcation.
Information gained from the study of hESCs has been used to
help improve the process of hiPSC generation, something that may
be advantageous for autologous stem cell therapies to progress to
the clinic. Understanding the mechanisms of pluripotency-
regulating miRNAs could be important in increasing the efﬁciency
of hiPSC generation. It has recently been found that induction of
miR-302 expression, either alone [75] or together with other ESC-
associated miRNAs [76], in human and mouse somatic cells
enables reprogramming to hiPSCs. This knowledge may lead to
improvements in the efﬁciency of hiPSC generation for stem cell
therapies.MiRNAs in ESC–EC differentiation
To allow for the differentiation of pluripotent stem cells, factors
and networks involved in the maintenance of pluripotency and
self-renewal are downregulated, and those involved in differentia-
tion and commitment of cells to speciﬁc lineages are upregulated.
A number of miRNAs involved in the maintenance and function of
vascular ECs, and those that are upregulated during hESC–EC
differentiation, have been identiﬁed. However, very little is cur-
rently known about the contribution of miRNAs to the differentia-
tion of this specialized cell type.
MiR-126, previously identiﬁed as a miRNA with a role in
endothelial cell structure and function (see earlier in this review),
was shown by Kane et al. [77] to be upregulated during hESC–EC
differentiation, performed using a feeder- and serum-free proto-
col. An increase in other endothelial angiogenesis-associated
miRNAs, including miR-210, -133a, -133b, -130a, and -296 and
let-7b and -7f, accompanied by a decrease in antiangiogenic
endothelial miRNAs, including miR-20a, -20b, -221, and -222,
was also observed after cells had been differentiated for 10 days,
although it was not determined whether any of these miRNAs are
speciﬁcally involved in the commitment or maturation of hESCs to
the endothelial lineage.
In an attempt to identify miRNAs involved in human EC
development, Kane et al. [57] further analyzed miRNAs during
the early stages of EC commitment from hESCs. From this study,
three miRNAs were identiﬁed, miR-181a, miR-181b, and miR-99b,
all of which are found in adult human ECs. MiR-99b is an
intergenic miRNA, which is transcribed in a cluster with both
miR-125a and let-7e, thus supporting previous work showing that
members of the let-7 family were induced upon EC cell differ-
entiation [77]. All three miRNAs were found to be upregulated in a
time- and differentiation-dependent manner. Overexpression of
either miR-99b or miR-181a during the differentiation resulted in
a signiﬁcant increase in the percentage of cells expressing both of
the endothelial markers Pecam-1 and VE-cadherin on day 10 of
the endothelial differentiation. This suggests that these miRNAs
can increase hESC–EC differentiation capacity when their levels are
manipulated and may speciﬁcally be involved in the commitment
of pluripotent stem cells to the vascular lineage.
As mentioned previously, the miR-17-92 cluster has also been
shown to play a role in endothelial cell function [78]. However,
recent studies of mESCs and miPSCs [79] have shown that,
although changes in the expression of the cluster occur, none of
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tion of pluripotent cells to the endothelial lineage. Knockdown of
the miRNAs in the miR-17-92 cluster using antagomirs, either
individually or in combination, had no effect on the expression of
pluripotency genes, mesoderm-associated genes, or endothelial
markers, and the morphology did not appear any different
between the antagomir-treated and the untreated cells. Therefore,
despite its importance in the regulation of vascular integrity and
angiogenesis, this cluster seems to have no effect on ESC–EC
differentiation [79] and is therefore more likely to regulate the
structure and function of mature ECs, rather than their formation.
As well as ECs, there are number of other important cell types
that also govern vascular integrity, including VSMCs. Differentia-
tion from pluripotent stem cell to VSMC is also controlled by a
network of miRNAs and genes. This has been previously reviewed
by Howard et al. [80], and understanding of this complex process
may also be important in the development of new vascular
regeneration strategies.Stem cell and miRNA therapies for vascular regeneration
Treatments to repair damaged vasculature resulting from a
range of vascular conditions, including hypertension and ischemia,
are currently limited. As discussed, stem cells are thought to have
great potential in the ﬁeld of regenerative medicine and, hence,
could provide solutions to the problem of vascular repair and
regeneration. It has also been speculated that miRNAs could play
an important role in the development and optimization of such
treatments, either as novel drug targets and as therapeutics
themselves, or as biomarkers, and miRNA proﬁles indicative of a
number of diseases, including cancer [81], coronary artery disease
[82], and diabetes [83], have already been identiﬁed.Oxidative stress, redox signaling, and miRNAs in vascular
development, regeneration, and ES cells
Reactive oxygen species (ROS) and redox signaling may also
play key roles in angiogenesis and vasculogenesis, as well as
functioning in stem and progenitor cell differentiation, prolifera-
tion, and senescence. Generated through a variety of processes,
ROS, such as superoxide anion (O2−) and hydrogen peroxide
(H2O2), have previously been shown to act as secondary messen-
gers in cell signal transduction [84]. The effects of ROS on signal
transduction-mediated biological events in cells have been shown
to be concentration dependent. At low levels, ROS function to
mediate both angiogenesis and vasculogenesis [85–87]. Excess
concentrations of ROS, however, can be toxic, leading to both EC
and stem and progenitor cell senescence and apoptosis [88].
Within endothelial, stem, and progenitor cells, one of the major
sources of ROS is NADPH oxidase [89]. NADPH oxidase comprises a
number of different subunits, including the catalytic gp91phox sub-
unit, which has several homologues [90]. In ECs the expression of
four different homologues has been observed, Nox1, Nox2, Nox4, and
Nox5; and in stem and progenitor cells it has been found that only
two of these homologues are expressed, Nox2 and Nox4. Activated
by a number of angiogenic signaling pathways and cytokines,
including VEGF, angiopoetin-1, and G-protein-coupled receptor
ligands, e.g. angiotensin II, NADPH oxidase and its derived ROS play
key roles in EC angiogenesis [91], as well as controlling proliferation,
migration, and differentiation in stem and progenitor cells.
ROS production and the oxidative state have also been shown
to be regulated by miRNAs, via the targeting of NADPH oxidase
and its subunits [92]. Knockdown of the Dicer processing enzyme
resulted in signiﬁcant impairment of the angiogenic response inhuman microvascular endothelial cells (HMECs), a phenomenon
that could be rescued by the addition of low concentrations of
H2O2. Dicer-knockdown HMECs also showed lower levels of
inducible ROS production, attributed to lower expression of
p47phox protein, a subunit of NADPH oxidase. Reduction in global
miRNA content induced an increase in the expression of the
transcription factor HBP1, which negatively regulates p47phox
expression, resulting in reduced redox signaling. It has also been
demonstrated that, during experimental diabetic nephropathy,
miR-25 may target the Nox4 subunit of NADPH oxidase [93],
henceforth regulating the production of O2− under these condi-
tions. As well as NADPH oxidase, superoxide dismutase (SOD), an
enzyme also responsible for the production of ROS, is also
regulated by a miRNA [94]. During cancer, miR-21 targets SOD to
regulate ROS production and promote tumorigenesis. These stu-
dies, therefore, highlight the importance of miRNAs in the control
of redox signaling and their ability to directly control the produc-
tion of ROS, in both ECs and other cell types, providing us with a
novel mechanism of control with great therapeutic potential.
Both stem and progenitor cells have low levels of baseline ROS
and, in hESCs, it has been shown that ROS can act to enhance
differentiation to the mesendoderm lineage [95]. Stimulation of
intracellular ROS generation in ES cells, via the application of
either an electrical ﬁeld [96] or mechanical strain [97], has also
been shown to stimulate cardiomyogenesis, as well as vascular
sprouting in embryoid bodies, caused through an increase in
NADPH oxidase expression, leading to increases in the levels of
hypoxia-inducible factor-1α and VEGF, knowledge that could be
useful for the application of therapeutic angiogenesis. Differentiat-
ing mESCs were also shown to display increased levels of vascu-
logenesis when stimulated with PDGF-BB, a factor shown to cause
an increase in Ca2+-mediated generation of ROS [98].
Indeed ROS may exert their effects through the targeting of
miRNAs. Recently, it has been shown that miR-200c, and the
cotranscribed miR-141, were upregulated when HUVECs were
treated with H2O2 in vitro [99]. Overexpression of miR-200c and
treatment with H2O2 caused HUVEC growth arrest, senescence,
and apoptosis, corresponding to an observed downregulation in
both the mRNA and the protein level of the miR-200c target ZEB1,
an effect that was partially rescued by the inhibition of miR-200c.
Inhibition of miR-200c may, therefore, be an important therapeu-
tic target in preventing the negative effects of oxidative stress on
cell function and survival.
MiRNA regulation of the oxidative state is a newly recognized
mechanism that has great potential therapeutically. Understand-
ing the mechanisms by which ROS act to govern both angiogenesis
and postnatal vasculogenesis, via the recruitment of stem and
progenitor cells, as well as their interaction with miRNAs, could
also have great potential in a clinical setting. Derivation of a
method of controlling the levels of ROS, or the activity of NADPH
oxidase, could in theory be used in the treatment of a number of
angiogenesis-dependent diseases, such as cancer, and for the
promotion of angiogenesis in ischemic injury.Concluding remarks
MicroRNAs are critical regulators of a number of important
cellular pathways and processes, and in recent years their roles in
governing vascular integrity and the development of vascular
dysfunction and CVD have been elucidated. In endothelial cells
miRNAs have important roles in both structure and function, and a
number of both anti- and proangiogenic miRNAs have been
identiﬁed. MiRNAs have also been found to play an important
role in the self-renewal and differentiation capacities of pluripo-
tent stem cells, a phenomenon that has been shown in a number
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including transcription factors, miRNAs contribute to the control of
the two deﬁning abilities of pluripotent stem cells; however, their
role in the commitment of stem cells to endothelial lineages is still
relatively poorly understood. Acquiring a better understanding of
how miRNAs regulate the commitment of cells to vascular
endothelial lineages, as well as their role in the structure and
function of mature endothelial cells, may have far-reaching impli-
cations in the development of new vascular regeneration strate-
gies, for the repair of damage resulting from ischemic injury.
Indeed, modulation of miRNAs identiﬁed as playing an important
role in the differentiation of hESCs to vascular lineages, as well as
those involved in governing vascular integrity, holds promise for a
range of clinical applications, including the derivation of more
efﬁcient differentiation protocols for the production of large
numbers of transplantable cells for vascular regeneration strate-
gies. Despite the ever-growing hope for new treatments that
accompanies each new advance in the ﬁeld of stem cell biology,
there are still a number of major problems, which must be
overcome before therapies begin to reach the clinic, including
safety, immune-speciﬁc issues, and survival of transplanted cells
[100]. Current focus, therefore, is on the use of stem cells as
in vitro models of development and disease, useful for the
identiﬁcation of new therapeutic targets. However, it is hoped
that in time many of the problems associated with the use of these
cells will be overcome as clinical experience develops, and that
such therapies may become more widely tested in diseases with
unmet clinical need.
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